nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2019-23-5-56-64nefr-1742Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESДислипидемия как патогенетический фактор прогрессирования хронической болезни почекDyslipidemia as a pathogenetic factor of the progression of the chronic kidney diseaseЛебедеваЕ. Н.LebedevaE. N.

Лебедева Елена Николаевна - кандидат биологических наук, доцент, кафедра биологической химии.

460000, г. Оренбург, ул. Советская, д. 6.

Тел.: (3532)774867; моб.: 8(950)1814090.

Elena N. Lebedeva - Аssociate Professor, PhD in Biology, Department of Biological Chemistry.

460000, Orenburg, Soviet st., 6.

Phone: (3532)774867; mob.: 8(950)1814090.

lebedeva.e.n@mail.ruhttps://orcid.org/0000-0002-6608-7888ВялковаА. А.VyalkovaA. A.

Вялкова Альбина Александровна – профессор, доктор медицинских наук, заведующая кафедрой факультетской педиатрии.

460000, г. Оренбург, ул. Советская, д. 6.

Тел.: 8(922)6258875.

Albina A. Vyalkova - MD, PhD, DMedSci, Head of Department of faculty Pediatrics.

460000, Orenburg, Soviet st., 6.

Рhone: 8(922)6258875.

k_pediatry@orgma.ruАфонинаС. Н.AfoninaS. N.

Афонина Светлана Николаевна - кандидат медицинских наук, доцент, кафедра биологической химии.

460000, г. Оренбург, ул. Советская, д. 6.

Тел.: (3532)774867.

Svetlana N. Afonina - Аssociate Professor, MD, PhD, Department of Biological Chemistry.

460000, Orenburg, Soviet st., 6.

Phone: 8(3532)774867; mob.: 8(950)1814090.

afonina_sn@mail.ruЧесноковаС. А.ChesnokovaS. A.

Чеснокова Светлана Александровна - аспирант кафедры факультетской педиатрии.

460000, г. Оренбург, ул. Советская, д. 6.

Тел.: 8(922)8858487.

Svetlana A. Chesnokova - full-time graduate student of the Department of faculty Pediatrics.

460000, Orenburg, Soviet st., 6.

Phone: 8(922)8858487.

d.s.a.dk@mail.ruОренбургский государственный медицинский университетРоссияOrenburg State Medical UniversityRussian Federation2019070820192355664Copyright © Лебедева Е.Н., Вялкова А.А., Афонина С.Н., Чеснокова С.А., 20192019Лебедева Е.Н., Вялкова А.А., Афонина С.Н., Чеснокова С.А.Lebedeva E.N., Vyalkova A.A., Afonina S.N., Chesnokova S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1742

В статье представлены современные сведения о патогенетической роли нарушений обмена липидов и значении липотоксичности при патологии почек, способствующих прогрессированию нефропатий. Выявленное повышение уровня ХС, ТАГ, ЛПНП, снижение концентрации ЛПВП в плазме крови при хронической болезни почек (ХБП) сопровождается значительными сдвигами в составе различных липопротеинов, обусловленных изменениями в экспрессии и активности ключевых белков и ферментов, участвующих в биосинтезе, транспорте, ремоделировании и катаболизме липидов и липопротеинов. Доказано, что дислипидемия при ХБП влияет на морфофункциональное состояние почек, способствуя развитию процессов почечной липотоксичности, оказывая воздействие на структурно-функциональное состояние почек, инициируя окислительный стресс, системное воспаление, повреждение сосудов и нарушение процессов регуляции. До настоящего времени исследования о значении дислипидемий, как патогенетического фактора формирования хронической болезни почек, остаются недостаточно изученными. Дисрегуляция липидного обмена, приводящая к дислипидемии, является часто недооцененным осложнением ХБП.

The article presents current information on the pathogenetic role of lipid metabolism disorders and the value of lipotoxicity in renal pathology, contributing to the progression of nephropathy. The detected increase in cholesterol level, TAG, LDL, decrease in plasma HDL concentration in chronic kidney disease (CKD) is accompanied by significant changes in the composition of various lipoproteins caused by changes in the expression and activity of key proteins and enzymes involved in the biosynthesis, transport, remodeling and catabolism of lipids and lipoproteins. It has been proven that dyslipidemia in CKD affects the morphological and functional state of the kidneys, contributing to the development of renal lipotoxicity processes, affecting the structural and functional state of the kidneys, initiating oxidative stress, systemic inflammation, vascular damage, and dysregulation. To date, research on the significance of dyslipidemia as a pathogenetic factor in the formation of chronic kidney disease remains insufficiently studied. Dysregulation of lipid metabolism, leading to dyslipidemia, is often an undervalued complication of CKD.

дислипидемиянефротоксичностьлипидылипопротеинынефросклерозdyslipidemianephrotoxicitylipidslipoproteinsnephrosclerosisReferencesСмирнов АВ, Шилов ЕМ, Добронравов ВА и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология 2012;16(1):89–115. doi: 10.24884/1561-6274-2012-16-1-89-115Smirnov AV, Shilov EM, Dobronravov VA et al. National guidelines. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nephrology (Saint-Petersburg) 2012;16(1):89–11. (In Russ.) doi: 10.24884/1561-6274-2012-16-1-89-115Lamb EJ, Levey AS, Stevens PE. The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not Revolution. Clinical Chemistry 2013;59(3):462–465. doi: 10.1373/clinchem.2012.184259Lamb EJ, Levey AS, Stevens PE. The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not Revolution. Clinical Chemistry 2013;59(3):462–465. doi: 10.1373/clinchem.2012.184259Agrawal S, Zaritsky JJ, Fornoni A. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018;14(1):57–70. doi: 10.1038/nrneph.2017.155Agrawal S, Zaritsky JJ, Fornoni A. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018;14(1):57–70. doi: 10.1038/nrneph.2017.155Вялкова АА, Николаева СН, Ушакова ЮВ и др. К вопросу ранней диагностики диабетической нефропатии у детей. Нефрология и диализ 2010;2:124–130Vyalkova AA, Nikolaev SN, Ushakova YuV et al. On the issue of early diagnosis of diabetic nephropathy in children. Nephrology and dialysis 2010;2:124–130 (In Russ.)Вялкова АА, Лебедева ЕН, Красиков СИ и др. Клинико-патогенетические аспекты повреждения почек при ожирении (обзор литературы). Нефрология 2014;18(3):24–33Vyalkova AA, Lebedeva EN, Krasikov SI et al. Clinical and pathogenetic aspects of kidney damage in obesity (review of literature). Nephrology (Saint-Petersburg) 2014;18(3):24–33 (In Russ.)Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017;13(10):629–646Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017;13(10):629–646Christensen EI, Nielsen R, Birn H. Renal Filtration, Transport, and Metabolism of Albumin and Albuminuria. Book Chapter published 2013 in Seldin and Giebisch's The Kidney:2457–2474. doi.org/10.1016/b978-0-12-381462-3.00073-2Christensen EI, Nielsen R, Birn H. Renal Filtration, Transport, and Metabolism of Albumin and Albuminuria. Book Chapter published 2013 in Seldin and Giebisch's The Kidney:2457–2474. doi.org/10.1016/b978-0-12-381462-3.00073-2Poronnik P, Nikolic-Paterson DJ. The proximal tubule and albuminuria – at last a starring role. Nature Reviews Nephrology 2015;11(10)):573–575. doi: 10.1038/nrneph.2015.127Poronnik P, Nikolic-Paterson DJ . The proximal tubule and albuminuria – at last a starring role. Nature Reviews Nephrology 2015;11(10)):573–575. doi: 10.1038/nrneph.2015.127Unger RH, Clark GO, Scherer PE et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010;1801:209–214. doi: 10.1016/j.bbalip.2009.10.006Unger RH, Clark GO, Scherer PE et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010;1801:209–214. doi: 10.1016/j.bbalip.2009.10.006Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010;19:393–402. doi: 10.1097/mnh.0b013e32833aa4acBobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010;19:393–402. doi: 10.1097/mnh.0b013e32833aa4acWayne D Comper. Is there equivalency of intact albuminuria and albumin peptideuria in nephrotic states? Kidney International 2013;84(5):1050. doi.org/10.1038/ki.2013.325Wayne D Comper. Is there equivalency of intact albuminuria and albumin peptideuria in nephrotic states? Kidney International 2013;84(5):1050. doi.org/10.1038/ki.2013.325Christensen EI, Birn H. Tubular handling of albumin – degradation or salvation? Nature Reviews Nephrology 2013; 9(12): 700–702. doi: 10.1038/nrneph.2013.212Christensen EI, Birn H. Tubular handling of albumin – degradation or salvation? Nature Reviews Nephrology 2013; 9(12): 700–702. doi: 10.1038/nrneph.2013.212Shaw SM, Fildes JE, Yonan N et al. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:4–12Shaw SM, Fildes JE, Yonan N et al. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:4–12Kronenberg F. HDL in CKD – the devil is in the detail. J Am Soc Nephrol 2018;29:1356–1371. doi: 10.1681/asn.2017070798Kronenberg F. HDL in CKD – the devil is in the detail. J Am Soc Nephrol 2018;29:1356–1371. doi: 10.1681/asn.2017070798Mange A, Goux A, Badiou S et al. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatographytandem mass spectrometry approach. PLoS One 2012;7:e34107. doi: 10.1371/journal.pone.0034107Mange A, Goux A, Badiou S et al. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatographytandem mass spectrometry approach. PLoS One 2012;7:e34107. doi: 10.1371/journal.pone.0034107Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934–947. doi: 10.1681/ASN.2011070668Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934–947. doi: 10.1681/ASN.2011070668Silbernagel G, Genser B, Drechsler C et al. HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients. J Am Soc Nephrol 2014;26:484–492. doi: 10.1681/ASN.2013080816Silbernagel G, Genser B, Drechsler C et al. HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients. J Am Soc Nephrol 2014;26:484–492. doi: 10.1681/ASN.2013080816Speer T, Rohrer L, Blyszczuk P et al. Abnormal highdensity lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013;38:754–768. doi: 10.1016/j.immuni.2013.02.009Speer T, Rohrer L, Blyszczuk P et al. Abnormal highdensity lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013;38:754–768. doi: 10.1016/j.immuni.2013.02.009Тугушева ФА, Зубина ИМ. Оксидативный стресс и его участие в неиммунных механизмах прогрессирования хронической болезни почек. Нефрология 2009;13(3):43–46. doi: 10.24884/1561-6274-2009-13-3-42-48Tugusheva FA, Zubina IM. Oxidative stress and its participation in the nonimmune mechanisms of the progression of chronic kidney disease. Nephrology (Saint-Petersburg) 2009;13(3):43–46. (In Russ.) doi: 10.24884/1561-6274-2009-13-3-42-48Calabresi L, Simonelli S, Conca P et al. Acquired lecithin: cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med 2015;277:552–561. doi: 10.1111/joim.12290Calabresi L, Simonelli S, Conca P et al. Acquired lecithin: cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med 2015;277:552–561. doi: 10.1111/joim.12290Mack S, Coassin S, Vaucher J et al. ApoA-IVGWAS Consortium Evaluating the causal relation of ApoAIV with disease-related traits – a bidirectional two-sample Mendelian randomization study. Sci Rep 2017;7:8734. doi: 10.1038/s41598-017-07213-9Mack S, Coassin S, Vaucher J et al. ApoA-IVGWAS Consortium Evaluating the causal relation of ApoAIV with disease-related traits – a bidirectional two-sample Mendelian randomization study. Sci Rep 2017;7:8734. doi: 10.1038/s41598-017-07213-9Bowe B, Xie Y, Xian H et al. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int 2016;89:886–896. doi: 10.1016/j.kint.2015.12.034Bowe B, Xie Y, Xian H et al. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int 2016;89:886–896. doi: 10.1016/j.kint.2015.12.034Aseem O, Smith BT, Cooley MA et al. Cubilin maintains blood levels of HDL and albumin. J Am Soc Nephrol 2014;25:1028–1036. doi: 10.1681/asn.2013060671Aseem O, Smith BT, Cooley MA et al. Cubilin maintains blood levels of HDL and albumin. J Am Soc Nephrol 2014;25:1028–1036. doi: 10.1681/asn.2013060671Bulbul MC. Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purif 2018;46(2):144–152. doi: 10.1159/000488816Bulbul MC. Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purif 2018;46(2):144–152. doi: 10.1159/000488816Савельева ЕВ, Вялкова АА. Характеристика сывороточного лептина и гемодинамических показателей почек у детей с сахарным диабетом 1 типа. Вестник Оренбургского государственного университета 2013;9:119–122Savelyeva EV, Vyalkova AA. Characteristics of serum leptin and hemodynamic parameters of the kidneys in children with type 1 diabetes. Bulletin of the Orenburg State University 2013;9:119–122 (In Russ.)Holzer M, Birner-Gruenberger R, Stojakovic T et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011;22:1631–1641. doi: 10.1681/ASN.2010111144Holzer M, Birner-Gruenberger R, Stojakovic T et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011;22:1631–1641. doi: 10.1681/ASN.2010111144Kaseda R, Jabs K, Hunley TE et al. Dysfunctional highdensity lipoproteins in children with chronic kidney disease. Metabolism 2015;64:263–273. doi: 10.1016/j.metabol.2014.10.020Kaseda R, Jabs K, Hunley TE et al. Dysfunctional highdensity lipoproteins in children with chronic kidney disease. Metabolism 2015;64:263–273. doi: 10.1016/j.metabol.2014.10.020Florens N, Calzada C, Lyasko E et al. Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins (Basel) 2016;8(12):376–403. doi: 10.3390/toxins8120376Florens N, Calzada C, Lyasko E et al. Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins (Basel) 2016;8(12):376–403. doi: 10.3390/toxins8120376Shroff R, Speer T, Colin S. HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol 2014;25:2658–2668. doi: 10.1681/asn.2013111212Shroff R, Speer T, Colin S. HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol 2014;25:2658–2668. doi: 10.1681/asn.2013111212Shao B, Heinecke JW. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. J Proteome 2011;74:2289–2299Shao B, Heinecke JW. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. J Proteome 2011;74:2289–2299Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 2013;9:617–670. doi: 10.2147/VHRM.S37119Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 2013;9:617–670. doi: 10.2147/VHRM.S37119Di Bartolo B, Scherer DJ, Brown A. PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook. Bio Drugs 2017; 31:167–174. doi: 10.1007/s40259-017-0220-yDi Bartolo B, Scherer DJ, Brown A. PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook. Bio Drugs 2017; 31:167–174. doi: 10.1007/s40259-017-0220-yVoulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 2011; 60(10):1456–1464. doi: 10.1016/j.metabol.2011.02.014Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 2011; 60(10):1456–1464. doi: 10.1016/j.metabol.2011.02.014Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 2016; 90(1): 41–52. doi: 10.1016/j.kint.2016.02.026Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 2016; 90(1): 41–52. doi: 10.1016/j.kint.2016.02.026Fornoni A, Sageshima J, WeiС et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Scitransl Med 2011;3(85):85ra46. doi: 10.1126/scitranslmed.3002231Fornoni A, Sageshima J, WeiС et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Scitransl Med 2011;3(85):85ra46. doi: 10.1126/scitranslmed.3002231Мельник АА. Нарушение липидного обмена и его коррекция при хронической болезни почек. Почки 2016;2(16):85–95Miller AA. Disruption of lipid metabolism and its correction in chronic kidney disease. Kidneys 2016;2(16):85–95 (In Russ.)Вялкова АА, Лебедева ЕН, Афонина СН и др. Заболевания почек и ожирение: молекулярные взаимосвязи и новые подходы к диагностике (обзор литературы). Нефрология 2017; 21(3):25–38. doi: 10.24884/1561-6274-2017-3-25-38Vyalkova AA, Lebedeva EN, Afonina CH et al. Kidney disease and obesity: molecular relationships and new approaches to diagnosis (literature review). Nephrology (Saint-Petersburg) 2017;21(3):25–38. (In Russ.) doi: 10.24884/1561-6274-2017-3-25-38Смирнов АВ, Каюков ИГ, Румянцев АШ. Проблема оценки скорости клубочковой фильтрации при ожирении. Нефрология 2017;21(2):20–23. doi: 10.24884/1561-6274-2017-21-2-20-23Smirnov AV, Kayukov IG, Rumyantsev ASh. The problem of assessing the glomerular filtration rate in obesity. Nephrology (Saint-Petersburg) 2017;21(2):20–23. (In Russ.) doi: 10.24884/1561-6274-2017-21-2-20-23

The authors declare that there are no conflicts of interest present.